Czura Thornton has signed an agreement to acquire the global central laboratory (GCL) operations of MDS Pharma Services, a business unit of MDS Pharma Services. Reportedly, GCL provides a range of late-stage laboratory and electrocardiogram services supporting clinical trials globally.
In a joint statement, Czura Thornton’s founders Tony Czura and Nick Thornton said: “Combined with our focus on the consistent delivery of high quality service and the flexibility and responsiveness that private ownership allows, we look forward to seeing renewed strength and growth in the business. While we see excellent opportunities for collaboration with Chiltern, a leading CRO also owned by Czura Thornton, the two entities will operate independently.”
Stephen DeFalco, president and CEO of MDS, said: “We are pleased that the agreement with Czura Thornton creates opportunities to build the Central Labs business, which includes world-class facilities and highly skilled people focused on delivering superior client service.”
The transaction is expected to close in the fourth quarter of 2009 and is subject to customary approvals and closing conditions.